20 August 2026 Clinical research Pharmaceuticals Psoriatic Athritis Sonelokimab clears phase 3 PsA hurdle
20 August 2026 Biologics Clinical research Psoriatic Athritis Oral TYK2 inhibitor holds PsA gains to one year
9 July 2026 Clinical research Obesity Psoriatic Athritis Higher BMI may blunt TNF inhibitor response in PsA
25 June 2026 Biologics Clinical research Psoriatic Athritis Bimekizumab outperforms risankizumab in head-to-head PsA trial
30 April 2026 SPONSORED Biologics Psoriatic Athritis Webinars Cracking the psoriatic arthritis treatment puzzle
13 November 2025 SPONSORED ACR Psoriatic Athritis Ultrasound breakthroughs could transform PsA diagnosis
24 July 2025 Clinical research Psoriatic Athritis Zasocitinib shows promise in psoriatic arthritis phase 2b trial
12 June 2025 Biologics EULAR Psoriatic Athritis Early biologic intervention yields lasting benefit in PsA
10 October 2024 PBS Pharmaceuticals Psoriatic Athritis Spondyloarthritis Bimekizumab added to PBS for PsA and axSpA patients
9 May 2024 Pharmaceuticals Psoriatic Athritis Spondyloarthritis TGA approves bimekizumab for PsA and axSpA
